Massive Bio and Optellum Collaborate to Accelerate Clinical Trial Access for Early-Stage Non-Small Cell Lung Cancer Patients
AI-powered lung cancer risk detection meets precision oncology trial matching - connecting high-risk patients to potentially life-saving research at the earliest, most treatable stage
Massive Bio, a global leader in AI-driven precision oncology and clinical trial matching operating across 17+ countries, and Optellum, the leader in AI-enabled lung cancer diagnosis and the developer of the world’s first FDA-cleared clinical decision support software for early-stage lung cancer, today announced a collaboration to bridge early lung cancer detection with clinical trial access for patients with non-small cell lung cancer (NSCLC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603987335/en/ Massive Bio and Optellum are joining forces to streamline clinical trial matching for early-stage non-small cell lung cancer patients through AI-driven precision oncology.
The collaboration represents a first-of-its-kind integration of Optellum’s clinically validated Lung Cancer Prediction (LCP) AI, which helps clinicians to surface high-risk lung nodule patients - with Massive Bio’s AI-powered clinical trial matching platform, which matches patients to active clinical trials and delivers actionable, physician-targeted reports. Together, the two companies aim to ensure that patients identified at high risk during routine imaging are not only diagnosed earlier but are promptly considered for clinical trials that could expand their treatment options.
